This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Discussing Janssen/Protagonist Therapeutics recent Icotrokinra Results Showing 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Ticker(s): JNJ, PTGX

Who's the expert?

Institution: 

  • Suburban dermatolgoist 
  • Manages 100+ patients with plaque psoriasis annually
  • Familiar with the recent clinical data for icotrokinra

Interview Goal
To discuss the recent Icotrokinra results and the overall plaque psoriasis treatment landscape.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.